PCM
TSVT

Penserra Capital Management’s 2seventy bio TSVT Stock Holding History

Penserra Capital Management’s Portfolio TSVT Stock Details TSVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-21,192
Closed -$83K – 1360
2023
Q3 		$83K Buy
21,192
+11,853
+127% +$77.7K ﹤0.01% 933
2023
Q2 		$94K Buy
9,339
+809
+9% +$8.56K ﹤0.01% 956
2023
Q1 		$87K Buy
8,530
+210
+3% +$2.4K ﹤0.01% 788
2022
Q4 		$77K Sell
8,320
-7,762
-48% -$109K ﹤0.01% 843
2022
Q3 		$233K Buy
16,082
+12,534
+353% +$186K 0.01% 594
2022
Q2 		$46K Buy
+3,548
New +$48.3K ﹤0.01% 921

Other funds holding TSVT

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
ECM
Engine Capital Management New York $828M AUM 6.49% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Penserra Capital Management's TSVT Position: Q4 2023 in Review

Penserra Capital Management sold out of 2seventy bio (TSVT) in Q4 2023, closing a stake of 21,192 shares — an estimated $83K sold.

Penserra Capital Management first reported a position in TSVT in Q2 2022 and held it in 6 quarters. The position peaked at $233K in Q3 2022. 116 funds tracked by Wall St. Rank hold TSVT as of Q4 2023.

  • Penserra Capital Management reported no remaining 2seventy bio position as of Q4 2023 after selling out during the quarter.
  • Penserra Capital Management sold 21,192 2seventy bio shares in Q4 2023, an estimated $83K.
  • Penserra Capital Management first reported a position in 2seventy bio in Q2 2022 and held it in 6 quarters.
  • Penserra Capital Management's 2seventy bio position peaked at $233K in Q3 2022.
  • 116 funds tracked by Wall St. Rank held 2seventy bio as of Q4 2023.

Based on Penserra Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.